Study of an FBXO7 patient mutation reveals Fbxo7 and PI 31 co‐regulate proteasomes and mitochondria
The FEBS Journal · 2024-06 · 291 (12) · 2565-2589
DOI: 10.1111/febs.17114 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, online erschienen am 11.03.2024. Verfasst von Sara Al Rawi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Cambridge, UK. Hauptthemen laut MEDLINE: F-Box Proteins, Proteasome Endopeptidase Complex, Mitochondria, Ubiquitination. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Biotechnology and Biological Sciences Research Council, NIHR Cambridge Biomedical Research Centre.
Abstract (Originalsprache)
Mutations in FBXO7 have been discovered to be associated with an atypical parkinsonism. We report here a new homozygous missense mutation in a paediatric patient that causes an L250P substitution in the dimerisation domain of Fbxo7. This alteration selectively ablates the Fbxo7‐PI31 interaction and causes a significant reduction in Fbxo7 and PI31 levels in patient cells. Consistent with their association with proteasomes, patient fibroblasts have reduced proteasome activity and proteasome subunits. We also show PI31 interacts with the MiD49/51 fission adaptor proteins, and unexpectedly, PI31 acts to facilitate SCF Fbxo7 ‐mediated ubiquitination of MiD49. The L250P mutation reduces the SCF Fbxo7 ligase‐mediated ubiquitination of a subset of its known substrates. Although MiD49/51 expression was reduced in patient cells, there was no effect on the mitochondrial network. However, patient cells show reduced levels of mitochondrial function and mitophagy, higher levels of ROS and are less viable under stress. Our study demonstrates that Fbxo7 and PI31 regulate proteasomes and mitochondria and reveals a new function for PI31 in enhancing the SCF Fbxo7 E3 ubiquitin ligase activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Cambridge, UK.
- Signalling and Structural Biology Laboratory, The Francis Crick Institute, London, UK.
- Department of Biological Sciences, Institute of Structural and Molecular Biology, London, UK.
- Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Medical Centre and Sackler Faculty of Medicine, Israel.
- Monique and Jacques Roboh Department of Genetic Research, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
- Mitochondrial Biology Unit, The MRC and University of Cambridge, UK.
ORCID-Profile: Massimo Zeviani, Heike Laman
Förderung
- Wellcome Trust
- Biotechnology and Biological Sciences Research Council
- NIHR Cambridge Biomedical Research Centre
- Cancer Research UK
- Rosetrees Trust
- Medical Research Council
- Parkinson's UK
Zitieren
APA
Al Rawi, S., Simpson, L., Agnarsdóttir, G., McDonald, N. Q., Chernuha, V., Elpeleg, O., Zeviani, M., Barker, R. A., Spiegel, R., & Laman, H. (2024). Study of an FBXO7 patient mutation reveals Fbxo7 and PI 31 co‐regulate proteasomes and mitochondria. The FEBS Journal, 291(12), 2565-2589. https://doi.org/10.1111/febs.17114
Vancouver
Al Rawi S, Simpson L, Agnarsdóttir G, McDonald NQ, Chernuha V, Elpeleg O, et al. Study of an FBXO7 patient mutation reveals Fbxo7 and PI 31 co‐regulate proteasomes and mitochondria. The FEBS Journal. 2024;291(12):2565-2589. doi:10.1111/febs.17114
BibTeX
@article{AlRawi2024,
author = {Al Rawi, Sara and Simpson, Lorna and Agnarsdóttir, Guðrún and McDonald, Neil Q and Chernuha, Veronika and Elpeleg, Orly and Zeviani, Massimo and Barker, Roger A and Spiegel, Ronen and Laman, Heike},
title = {Study of an FBXO7 patient mutation reveals Fbxo7 and PI 31 co‐regulate proteasomes and mitochondria},
journal = {The FEBS Journal},
year = {2024},
volume = {291},
number = {12},
pages = {2565--2589},
doi = {10.1111/febs.17114}
}
EUVIMED